| REGISTERED NUMBER: 12267717 (England and Wales) |
| Group Strategic Report, Report of the Directors and |
| Consolidated Financial Statements for the Year Ended 31 December 2024 |
| for |
| Alpha-Cure Group Limited |
| REGISTERED NUMBER: 12267717 (England and Wales) |
| Group Strategic Report, Report of the Directors and |
| Consolidated Financial Statements for the Year Ended 31 December 2024 |
| for |
| Alpha-Cure Group Limited |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Contents of the Consolidated Financial Statements |
| for the Year Ended 31 December 2024 |
| Page |
| Company Information | 1 |
| Group Strategic Report | 2 |
| Report of the Directors | 4 |
| Report of the Independent Auditors | 6 |
| Consolidated Income Statement | 10 |
| Consolidated Other Comprehensive Income | 11 |
| Consolidated Balance Sheet | 12 |
| Company Balance Sheet | 14 |
| Consolidated Statement of Changes in Equity | 16 |
| Company Statement of Changes in Equity | 17 |
| Consolidated Cash Flow Statement | 18 |
| Notes to the Consolidated Cash Flow Statement | 19 |
| Notes to the Consolidated Financial Statements | 21 |
| Alpha-Cure Group Limited |
| Company Information |
| for the Year Ended 31 December 2024 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| AUDITORS: |
| Statutory Auditors |
| Chartered Accountants |
| 1 Lucas Bridge Business Park |
| 1 Old Greens Norton Road |
| Towcester |
| Northamptonshire |
| NN12 8AX |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Group Strategic Report |
| for the Year Ended 31 December 2024 |
| The directors present their strategic report of the company and the group for the year ended 31 December 2024. |
| BUSINESS OVERVIEW |
| Alpha-Cure is recognised globally for delivering the highest quality UV lamp technology directly to end-users, and working in partnership with leading UV system manufacturers around the world. Established in 1996 Alpha-Cure is a specialist manufacturer of ultraviolet (UV) curing and metal halide lamps. |
| Our mission is to be the leading manufacturer and supplier within the UV industry and to grow our worldwide reach. We will achieve our mission by continuing to develop our portfolio of UV products focused on technology innovations whilst delivering excellent customer service and ensuring employee satisfaction. |
| The continuing development of new products and innovative manufacturing processes, along with continuing improvements made to the usable lives of existing products, have significantly contributed to the group's growth and ensures that the Alpha-Cure Group remains at the forefront of the UV and Metal Halide lamp industry. |
| With our knowledge of the industry and focussed direction of management, we feel confident that the group will continue to do well, despite the current challenges to the world economy. |
| BUSINESS MODEL |
| We operate a vertically integrated model, managing product design, manufacturing and distribution, through our worldwide network in Europe, Asia, North America and Australia Asia. |
| Revenue is generated through direct sales and developing these long-term relationships. |
| STRATEGY |
| Our strategic priorities for the next three years include: |
| Market Expansion: Entering new niche uses for the products and entering new regional markets across Europe, North America. |
| Innovation: Investing in R&D to develop to expand the markets in which our products operate The Company is continually developing its manufacturing processes and product range so as to keep up with ever changing demand from customers and machinery manufacturers. |
| Sustainability and the environment: We will always work towards ensuring that our company reduces the impact on the environment when operating our business management system and seek continual improvement |
| PRINCIPAL RISKS AND UNCERTAINTIES |
| Regulatory Risk: Changes in government regulation could impact demand. |
| Supply Chain Disruption: Global economic trade changes between countries. |
| Innovation: Changing demand from customers and machinery manufacturers. |
| Each risk is monitored by the management and mitigated through supplier diversification, regular reviews and proactive regulatory engagement. |
| FINANCIAL KEY PERFORMANCE INDICATORS |
| The Directors have monitored the progress of the overall group strategy and the individual strategic elements by reference to certain key performance indicators. |
| Turnover: £10,918,552 (2023 - £10,744,658) |
| Gross profit margin: 55.7% (2023 - 55.4%) |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Group Strategic Report |
| for the Year Ended 31 December 2024 |
| FUTURE OUTLOOK |
| We anticipate strong demand driven by accelerating adoption and use of our products, through increase use, new technology, new sector uses and market expansion. |
| This is backed by "UV Curing System Market Forecast to 2028" estimated a compound annual growth rate of 9.0% from 2021 to 2028, |
| ON BEHALF OF THE BOARD: |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Report of the Directors |
| for the Year Ended 31 December 2024 |
| The directors present their report with the financial statements of the company and the group for the year ended 31 December 2024. |
| PRINCIPAL ACTIVITY |
| The principal activity of the group in the year under review was that of the manufacture and sale of UV and Metal Halide lamps. |
| DIVIDENDS |
| The total distribution of dividends for the year ended 31 December 2024 was £1,793,700. |
| DIRECTORS |
| The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report. |
| FINANCIAL INSTRUMENTS |
| The group uses various financial instruments including cash, trade debtors, and trade creditors that arise |
| directly from the group's operations. |
| The existence of these financial instruments exposes the group to a number of financial risks, which are described in more detail below. |
| The main risks arising from the group's financial instruments are liquidity risk, interest rate risk and credit risk. The |
| directors review and agree policies for managing each of these risks and they are summarised below: |
| LIQUIDITY RISK |
| The group seeks to manage finance risk by ensuring sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably. |
| INTEREST RATE RISK |
| The group finances its operations through a mixture of retained profits and cash balances. Cash is managed to |
| maximise income from interest while avoiding inherent risk. |
| CREDIT RISK |
| The group's principle financial assets are cash and trade debtors. |
| In order to manage credit risk the directors set limits for customers based on a combination of payment history and third party credit references. Credit limits are reviewed by the credit controller on a regular basis in conjunction with debt ageing and collection history. |
| STATEMENT OF DIRECTORS' RESPONSIBILITIES |
| The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations. |
| Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to: |
| - | select suitable accounting policies and then apply them consistently; |
| - | make judgements and accounting estimates that are reasonable and prudent; |
| - | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Report of the Directors |
| for the Year Ended 31 December 2024 |
| STATEMENT OF DIRECTORS' RESPONSIBILITIES - continued |
| The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. |
| STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS |
| So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information. |
| AUDITORS |
| The auditors, CED Accountancy Services Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting. |
| ON BEHALF OF THE BOARD: |
| Report of the Independent Auditors to the Members of |
| Alpha-Cure Group Limited |
| Opinion |
| We have audited the financial statements of Alpha-Cure Group Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). |
| In our opinion the financial statements: |
| - | give a true and fair view of the state of the group's and of the parent company affairs as at 31 December 2024 and of the group's profit for the year then ended; |
| - | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
| - | have been prepared in accordance with the requirements of the Companies Act 2006. |
| Basis for opinion |
| We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. |
| Conclusions relating to going concern |
| In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. |
| Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. |
| Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. |
| Other information |
| The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon. |
| Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. |
| In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. |
| Opinions on other matters prescribed by the Companies Act 2006 |
| In our opinion, based on the work undertaken in the course of the audit: |
| - | the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
| - | the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements. |
| Report of the Independent Auditors to the Members of |
| Alpha-Cure Group Limited |
| Matters on which we are required to report by exception |
| In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors. |
| We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: |
| - | adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or |
| - | the parent company financial statements are not in agreement with the accounting records and returns; or |
| - | certain disclosures of directors' remuneration specified by law are not made; or |
| - | we have not received all the information and explanations we require for our audit. |
| Responsibilities of directors |
| As explained more fully in the Statement of Directors' Responsibilities set out on pages four and five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. |
| In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so. |
| Report of the Independent Auditors to the Members of |
| Alpha-Cure Group Limited |
| Auditors' responsibilities for the audit of the financial statements |
| Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
| The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: |
| The engagement partner ensured that the engagement team had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations; |
| we identified the laws and regulations applicable to the company through discussions with directors and other management; |
| we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation, employment environmental and health and safety legislation; |
| we assessed the extent of compliance with the laws and regulations identified above; |
| we communicated identified laws and regulations within the audit team who remained alert to instances of non-compliance. |
| We assessed the susceptibility of the company's financial statements to material misstatement including obtaining an understanding of how fraud might occur, by; |
| - making enquiries of management as to whether they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; |
| - considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations; and |
| -understanding the design of the company's remuneration policies. |
| To address the risk of fraud through management bias and override of controls, we; |
| - performed analytical procedures to identify any unusual or unexpected relationships; |
| - tested journal entries to identify unusual transactions; |
| In response to the risk of non-compliance with laws and regulations, we designed procedures which included, but were not limited to; |
| - agreeing financial statement disclosures to underlying supporting documentation; |
| - enquiring of management as to actual and potential litigation and claims; and |
| - reviewing correspondence with HMRC and the company's legal advisors. |
| There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any. |
| Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion. |
| A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors. |
| Report of the Independent Auditors to the Members of |
| Alpha-Cure Group Limited |
| Use of our report |
| This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed. |
| for and on behalf of |
| Statutory Auditors |
| Chartered Accountants |
| 1 Lucas Bridge Business Park |
| 1 Old Greens Norton Road |
| Towcester |
| Northamptonshire |
| NN12 8AX |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Income Statement |
| for the Year Ended 31 December 2024 |
| 31.12.24 | 31.12.23 |
| Notes | £ | £ | £ | £ |
| TURNOVER | 3 | 10,918,552 | 10,744,658 |
| Cost of sales | 4,834,441 | 4,789,532 |
| GROSS PROFIT | 6,084,111 | 5,955,126 |
| Distribution costs | 874,307 | 911,779 |
| Administrative expenses | 2,836,928 | 3,013,767 |
| 3,711,235 | 3,925,546 |
| 2,372,876 | 2,029,580 |
| Other operating income | 8,139 | 84,363 |
| OPERATING PROFIT | 5 | 2,381,015 | 2,113,943 |
| Income from shares in group undertakings | - | 28,600 |
| Income from interest in associated undertakings |
(6,845 |
) |
(19,050 |
) |
| Interest receivable and similar income | 1,051 | 328 |
| (5,794 | ) | 9,878 |
| 2,375,221 | 2,123,821 |
| Interest payable and similar expenses | 6 | 17,873 | 62,472 |
| PROFIT BEFORE TAXATION | 2,357,348 | 2,061,349 |
| Tax on profit | 7 | 495,365 | 234,150 |
| PROFIT FOR THE FINANCIAL YEAR |
| Profit attributable to: |
| Owners of the parent | 1,971,437 | 1,909,557 |
| Non-controlling interests | (109,454 | ) | (82,358 | ) |
| 1,861,983 | 1,827,199 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Other Comprehensive Income |
| for the Year Ended 31 December 2024 |
| 31.12.24 | 31.12.23 |
| Notes | £ | £ |
| PROFIT FOR THE YEAR | 1,861,983 | 1,827,199 |
| OTHER COMPREHENSIVE INCOME |
| Foreign exchange | (50,447 | ) | (581,499 | ) |
| Income tax relating to other comprehensive income |
- |
- |
| OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF INCOME TAX |
(50,447 |
) |
(581,499 |
) |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
1,811,536 |
1,245,700 |
| Total comprehensive income attributable to: |
| Owners of the parent | 1,920,991 | 1,328,058 |
| Non-controlling interests | (109,455 | ) | (82,358 | ) |
| 1,811,536 | 1,245,700 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Balance Sheet |
| 31 December 2024 |
| 31.12.24 | 31.12.23 |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Intangible assets | 10 | 922,684 | 665 |
| Tangible assets | 11 | 3,046,630 | 3,275,775 |
| Investments | 12 |
| Interest in associate | 202,198 | 209,043 |
| Other investments | 747 | 783 |
| 4,172,259 | 3,486,266 |
| CURRENT ASSETS |
| Stocks | 13 | 3,043,479 | 2,868,219 |
| Debtors | 14 | 2,661,449 | 2,217,966 |
| Cash at bank and in hand | 1,977,425 | 2,404,685 |
| 7,682,353 | 7,490,870 |
| CREDITORS |
| Amounts falling due within one year | 15 | 2,004,612 | 1,387,997 |
| NET CURRENT ASSETS | 5,677,741 | 6,102,873 |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
9,850,000 |
9,589,139 |
| CREDITORS |
| Amounts falling due after more than one year |
16 |
(320,271 |
) |
(24,019 |
) |
| PROVISIONS FOR LIABILITIES | 20 | (128,966 | ) | (182,192 | ) |
| NET ASSETS | 9,400,763 | 9,382,928 |
| CAPITAL AND RESERVES |
| Called up share capital | 21 | 6,000 | 6,000 |
| Retained earnings | 22 | 6,496,740 | 6,369,450 |
| SHAREHOLDERS' FUNDS | 6,502,740 | 6,375,450 |
| NON-CONTROLLING INTERESTS | 2,898,023 | 3,007,478 |
| TOTAL EQUITY | 9,400,763 | 9,382,928 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Balance Sheet - continued |
| 31 December 2024 |
| The financial statements were approved by the Board of Directors and authorised for issue on 30 September 2025 and were signed on its behalf by: |
| M A Slater - Director |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Company Balance Sheet |
| 31 December 2024 |
| 31.12.24 | 31.12.23 |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Intangible assets | 10 |
| Tangible assets | 11 |
| Investments | 12 |
| CURRENT ASSETS |
| Debtors | 14 |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CAPITAL AND RESERVES |
| Called up share capital | 21 |
| Other reserves | 22 |
| SHAREHOLDERS' FUNDS |
| Company's profit for the financial year | 1,184,400 | 521,400 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Company Balance Sheet - continued |
| 31 December 2024 |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Statement of Changes in Equity |
| for the Year Ended 31 December 2024 |
| Called up |
| share | Retained | Non-controlling | Total |
| capital | earnings | Total | interests | equity |
| £ | £ | £ | £ | £ |
| Balance at 1 January 2023 | 6,000 | 5,869,478 | 5,875,478 | 3,089,836 | 8,965,314 |
| Changes in equity |
| Dividends | - | (828,086 | ) | (828,086 | ) | - | (828,086 | ) |
| Total comprehensive income | - | 1,328,058 | 1,328,058 | (82,358 | ) | 1,245,700 |
| Balance at 31 December 2023 | 6,000 | 6,369,450 | 6,375,450 | 3,007,478 | 9,382,928 |
| Changes in equity |
| Dividends | - | (1,793,700 | ) | (1,793,700 | ) | - | (1,793,700 | ) |
| Total comprehensive income | - | 1,920,990 | 1,920,990 | (109,455 | ) | 1,811,535 |
| Balance at 31 December 2024 | 6,000 | 6,496,740 | 6,502,740 | 2,898,023 | 9,400,763 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Company Statement of Changes in Equity |
| for the Year Ended 31 December 2024 |
| Called up |
| share | Retained | Other | Total |
| capital | earnings | reserves | equity |
| £ | £ | £ | £ |
| Balance at 1 January 2023 |
| Changes in equity |
| Dividends | - | ( |
) | - | ( |
) |
| Total comprehensive income | - |
| Balance at 31 December 2023 |
| Changes in equity |
| Dividends | - | ( |
) | - | ( |
) |
| Total comprehensive income | - |
| Balance at 31 December 2024 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Consolidated Cash Flow Statement |
| for the Year Ended 31 December 2024 |
| 31.12.24 | 31.12.23 |
| Notes | £ | £ |
| Cash flows from operating activities |
| Cash generated from operations | 1 | 2,752,761 | 2,465,730 |
| Interest paid | (13,724 | ) | (60,324 | ) |
| Interest element of hire purchase payments paid |
(2,298 |
) |
(1,182 |
) |
| Finance costs paid | (1,851 | ) | (966 | ) |
| Tax paid | (337,463 | ) | (529,212 | ) |
| Net cash from operating activities | 2,397,425 | 1,874,046 |
| Cash flows from investing activities |
| Purchase of intangible fixed assets | (950,294 | ) | - |
| Purchase of tangible fixed assets | (335,673 | ) | (381,377 | ) |
| Sale of tangible fixed assets | 119,040 | 38,794 |
| Decrease in investment in associate | (6,845 | ) | 19,050 |
| Interest received | 1,051 | 328 |
| Dividends received | - | 28,600 |
| Net cash from investing activities | (1,172,721 | ) | (294,605 | ) |
| Cash flows from financing activities |
| New loans in year | 390,000 | - |
| Loan repayments in year | (32,872 | ) | (45,000 | ) |
| New HP in year | 6,845 | - |
| Capital repayments in year | (20,443 | ) | (12,166 | ) |
| Amount introduced by directors | 228,329 | 204,441 |
| Amount withdrawn by directors | (191,753 | ) | (504,309 | ) |
| Equity dividends paid | (1,793,700 | ) | (828,086 | ) |
| Net cash from financing activities | (1,413,594 | ) | (1,185,120 | ) |
| (Decrease)/increase in cash and cash equivalents | (188,890 | ) | 394,321 |
| Cash and cash equivalents at beginning of year |
2 |
2,166,315 |
1,771,994 |
| Cash and cash equivalents at end of year | 2 | 1,977,425 | 2,166,315 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Cash Flow Statement |
| for the Year Ended 31 December 2024 |
| 1. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Profit before taxation | 2,357,348 | 2,061,349 |
| Depreciation charges | 426,727 | 411,785 |
| (Profit)/loss on disposal of fixed assets | (41,731 | ) | 15,287 |
| Foreign exchange | 114,992 | (321,861 | ) |
| Finance costs | 17,873 | 62,472 |
| Finance income | 5,794 | (9,878 | ) |
| 2,881,003 | 2,219,154 |
| (Increase)/decrease in stocks | (175,260 | ) | 305,121 |
| (Increase)/decrease in trade and other debtors | (499,913 | ) | 81,342 |
| Increase/(decrease) in trade and other creditors | 546,931 | (139,887 | ) |
| Cash generated from operations | 2,752,761 | 2,465,730 |
| 2. | CASH AND CASH EQUIVALENTS |
| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts: |
| Year ended 31 December 2024 |
| 31.12.24 | 1.1.24 |
| £ | £ |
| Cash and cash equivalents | 1,977,425 | 2,404,685 |
| Bank overdrafts | - | (238,370 | ) |
| 1,977,425 | 2,166,315 |
| Year ended 31 December 2023 |
| 31.12.23 | 1.1.23 |
| £ | £ |
| Cash and cash equivalents | 2,404,685 | 1,771,994 |
| Bank overdrafts | (238,370 | ) | - |
| 2,166,315 | 1,771,994 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Cash Flow Statement |
| for the Year Ended 31 December 2024 |
| 3. | ANALYSIS OF CHANGES IN NET FUNDS |
| Other |
| non-cash |
| At 1.1.24 | Cash flow | changes | At 31.12.24 |
| £ | £ | £ | £ |
| Net cash |
| Cash at bank |
| and in hand | 2,404,685 | (427,260 | ) | 1,977,425 |
| Bank overdrafts | (238,370 | ) | 238,370 | - |
| 2,166,315 | (188,890 | ) | 1,977,425 |
| Debt |
| Finance leases | (41,093 | ) | 11,301 | (58,708 | ) | (88,500 | ) |
| Debts falling due |
| within 1 year | - | (97,500 | ) | - | (97,500 | ) |
| Debts falling due |
| after 1 year | - | (268,125 | ) | - | (268,125 | ) |
| (41,093 | ) | (354,324 | ) | (58,708 | ) | (454,125 | ) |
| Total | 2,125,222 | (543,214 | ) | (58,708 | ) | 1,523,300 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements |
| for the Year Ended 31 December 2024 |
| 1. | STATUTORY INFORMATION |
| Alpha-Cure Group Limited is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Basis of consolidation |
| The Group and all its subsidiary undertakings, except where the subsidiary is immaterial to the group in size and or function, are consolidated. Intercompany transactions and balances among Group companies are eliminated in full. The Group's share of results from associates are accounted for using equity accounting principles. The results and fair values of the assets and liabilities of undertakings acquired are consolidated from the date on which the Group gains control. The results from discontinued operations are included up until the date on which they are disposed of or terminated. Where, in the view of the directors, the Group does not have de facto control over the related entities, these entities are excluded from the consolidation in the Group's financial statements. Business combinations are accounted for using the purchase method of accounting under FRS 102, Section 19 Business Combinations. In the balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at fair value at the date of acquisition (which is the date on which control is passed to the parent). The results of the acquired operations are included in the consolidated profit and loss account from the date of acquisition. Consolidation ceases from the date on which control ceases. |
| Related party exemption |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |
| Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements. |
| Significant judgements and estimates |
| In the application of the company's accounting policies management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. |
| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Turnover comprises the fair value of the consideration received or receivable for the sale of lamps and lighting components to customers in the ordinary course of the group's activities. |
| Turnover is shown net of value added tax, returns, rebates and discounts. |
| The group recognises revenue when: |
| The amount of revenue can be reliably measured; |
| it is probable that future economic benefits will flow to the entity: |
| and specific criteria have been met for each of the group's activities. |
| Goodwill |
| In September 2024, the company purchased production line assets from USA for $1,500,000. This product line manufactures pressure lamps which incorporate UV technology. Goodwill on purchase was valued at £928,619 and is being written off over its estimated useful life of 10 years. |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
| Tangible fixed assets |
| Freehold property | - |
| Short leasehold | - |
| Plant and machinery | - |
| Fixtures and fittings | - |
| Motor vehicles | - |
| Computer equipment | - |
| Investments in associates |
| Investments in associate undertakings are recognised at cost. |
| Stocks |
| Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Financial instruments |
| The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, bank overdrafts, loans to related parties and investments in non-puttable ordinary shares. |
| Debt instruments (other than those wholly repayable or receivable within one year), including loans and other |
| accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest rate method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in a case of an out-right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost. |
| Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Income Statement. |
| For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. |
| For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive if the asset were to be sold at the reporting date. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Research and development |
| Expenditure on research and development is written off in the year in which it is incurred. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Foreign currencies |
| Functional and presentation currency |
| The Group’s financial statements are presented in Sterling (£) and rounded to thousands (unless stated otherwise). The individual financial statements of each Group entity are prepared in the currency of the primary economic environment in which the entity operates (its functional currency). These financial statements are then translated into the Group’s presentation currency for consolidation purposes as described below. |
| The Company’s functional and presentational currency is Sterling. |
| Transactions and balances |
| In preparing the financial statements of the individual entities, transactions in currencies other than the functional currency of the individual entities (foreign currencies) are recognised at the spot rate at the dates of the transactions, or at an average rate where this rate approximates the actual rate at the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Nonmonetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. |
| Exchange differences are recognised in profit or loss in the period in which they arise. However, in the consolidated financial statements exchange differences arising on monetary items that form part of the net investment in a foreign operation are recognised in other comprehensive income and are not reclassified to profit or loss. |
| Translation of group companies |
| For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated from their functional currency to Sterling using the closing exchange rate. Income and expenses are translated using the average rate for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are used. |
| Exchange differences arising on the translation of group companies are recognised in other comprehensive income. If the Group disposes of the foreign operation the cumulative exchange difference is not reclassified to profit or loss but is transferred within equity to retained earnings. |
| Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate. |
| Hire purchase and leasing commitments |
| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter. |
| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability. |
| Pension costs and other post-retirement benefits |
| The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 3. | TURNOVER |
| The turnover and profit before taxation are attributable to the one principal activity of the group. |
| An analysis of turnover by geographical market is given below: |
| 31.12.24 | 31.12.23 |
| £ | £ |
| United Kingdom | 4,600,880 | 4,271,442 |
| Europe | 1,957,706 | 1,860,326 |
| Rest of the World | 4,359,966 | 4,612,890 |
| 10,918,552 | 10,744,658 |
| 4. | EMPLOYEES AND DIRECTORS |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Wages and salaries | 2,557,717 | 3,065,177 |
| Social security costs | 169,070 | 208,238 |
| Other pension costs | 113,164 | 81,463 |
| 2,839,951 | 3,354,878 |
| The average number of employees during the year was as follows: |
| 31.12.24 | 31.12.23 |
| Manufacturing | 67 | 72 |
| Sales and administration | 42 | 48 |
| The average number of employees by undertakings that were proportionately consolidated during the year was 109 (2023 - 120 ) . |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Directors' remuneration | 211,139 | 195,536 |
| Directors' pension contributions to money purchase schemes | 60,437 | 14,302 |
| The number of directors to whom retirement benefits were accruing was as follows: |
| Money purchase schemes | 3 | 3 |
| Information regarding the highest paid director for the year ended 31 December 2024 is as follows: |
| 31.12.24 |
| £ |
| Emoluments etc | 73,433 |
| Pension contributions to money purchase schemes | 14,000 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 5. | OPERATING PROFIT |
| The operating profit is stated after charging/(crediting): |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Depreciation - owned assets | 418,299 | 413,824 |
| Depreciation - assets on hire purchase contracts | 11,322 | 3,774 |
| (Profit)/loss on disposal of fixed assets | (41,731 | ) | 15,287 |
| Goodwill amortisation | 27,085 | - |
| Patents and licences amortisation | 1,190 | 288 |
| Auditors' remuneration | 6,820 | 5,000 |
| Auditors' remuneration for non audit work | 13,104 | 13,104 |
| 6. | INTEREST PAYABLE AND SIMILAR EXPENSES |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Bank interest | 13,413 | 38,750 |
| Pension loan interest | - | 7,803 |
| HMRC interest | 311 | 13,771 |
| Hire purchase | 2,298 | 1,182 |
| Fines and penalties | 1,851 | 966 |
| 17,873 | 62,472 |
| 7. | TAXATION |
| Analysis of the tax charge |
| The tax charge on the profit for the year was as follows: |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Current tax: |
| UK corporation tax | 542,247 | 224,567 |
| Prior year over/underprovision | 6,344 | (15,548 | ) |
| Total current tax | 548,591 | 209,019 |
| Deferred tax | (53,226 | ) | 25,131 |
| Tax on profit | 495,365 | 234,150 |
| UK corporation tax has been charged at 25 % (2023 - 23.50 %). |
| Tax effects relating to effects of other comprehensive income |
| 31.12.24 |
| Gross | Tax | Net |
| £ | £ | £ |
| Foreign exchange | (50,447 | ) | - | (50,447 | ) |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 7. | TAXATION - continued |
| 31.12.23 |
| Gross | Tax | Net |
| £ | £ | £ |
| Foreign exchange | (581,499 | ) | - | (581,499 | ) |
| 8. | INDIVIDUAL INCOME STATEMENT |
| As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements. |
| 9. | DIVIDENDS |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Ordinary shares of £1 each |
| Interim | 1,793,700 | 828,086 |
| 10. | INTANGIBLE FIXED ASSETS |
| Group |
| Patents |
| and |
| Goodwill | licences | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2024 | - | 5,727 | 5,727 |
| Additions | 928,619 | 21,675 | 950,294 |
| At 31 December 2024 | 928,619 | 27,402 | 956,021 |
| AMORTISATION |
| At 1 January 2024 | - | 5,062 | 5,062 |
| Amortisation for year | 27,085 | 1,190 | 28,275 |
| At 31 December 2024 | 27,085 | 6,252 | 33,337 |
| NET BOOK VALUE |
| At 31 December 2024 | 901,534 | 21,150 | 922,684 |
| At 31 December 2023 | - | 665 | 665 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 11. | TANGIBLE FIXED ASSETS |
| Group |
| Freehold | Short | Plant and |
| property | leasehold | machinery |
| £ | £ | £ |
| COST |
| At 1 January 2024 | 2,580,344 | 227,411 | 4,024,202 |
| Additions | - | - | 279,875 |
| Disposals | (674 | ) | - | (147,141 | ) |
| Exchange differences | (29,108 | ) | - | (16,274 | ) |
| Transfer to ownership | - | - | (79,438 | ) |
| At 31 December 2024 | 2,550,562 | 227,411 | 4,061,224 |
| DEPRECIATION |
| At 1 January 2024 | 440,297 | 122,951 | 3,309,429 |
| Charge for year | 111,957 | 19,202 | 206,097 |
| Eliminated on disposal | - | - | (90,198 | ) |
| Exchange differences | (4,967 | ) | - | (5,412 | ) |
| At 31 December 2024 | 547,287 | 142,153 | 3,419,916 |
| NET BOOK VALUE |
| At 31 December 2024 | 2,003,275 | 85,258 | 641,308 |
| At 31 December 2023 | 2,140,047 | 104,460 | 714,773 |
| Fixtures |
| and | Motor | Computer |
| fittings | vehicles | equipment | Totals |
| £ | £ | £ | £ |
| COST |
| At 1 January 2024 | 1,111,982 | 157,442 | 3,689 | 8,105,070 |
| Additions | 92,812 | 20,869 | 825 | 394,381 |
| Disposals | - | (22,346 | ) | - | (170,161 | ) |
| Exchange differences | (2,482 | ) | (2,113 | ) | (172 | ) | (50,149 | ) |
| Transfer to ownership | - | - | - | (79,438 | ) |
| At 31 December 2024 | 1,202,312 | 153,852 | 4,342 | 8,199,703 |
| DEPRECIATION |
| At 1 January 2024 | 910,261 | 43,616 | 2,741 | 4,829,295 |
| Charge for year | 60,603 | 30,162 | 1,600 | 429,621 |
| Eliminated on disposal | - | (2,654 | ) | - | (92,852 | ) |
| Exchange differences | (1,187 | ) | (1,297 | ) | (128 | ) | (12,991 | ) |
| At 31 December 2024 | 969,677 | 69,827 | 4,213 | 5,153,073 |
| NET BOOK VALUE |
| At 31 December 2024 | 232,635 | 84,025 | 129 | 3,046,630 |
| At 31 December 2023 | 201,721 | 113,826 | 948 | 3,275,775 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 11. | TANGIBLE FIXED ASSETS - continued |
| Group |
| Fixed assets, included in the above, which are held under hire purchase contracts are as follows: |
| Fixtures |
| and | Motor |
| fittings | vehicles | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2024 | - | 45,289 | 45,289 |
| Additions | 58,708 | - | 58,708 |
| At 31 December 2024 | 58,708 | 45,289 | 103,997 |
| DEPRECIATION |
| At 1 January 2024 | - | 3,774 | 3,774 |
| Charge for year | - | 11,322 | 11,322 |
| At 31 December 2024 | - | 15,096 | 15,096 |
| NET BOOK VALUE |
| At 31 December 2024 | 58,708 | 30,193 | 88,901 |
| At 31 December 2023 | - | 41,515 | 41,515 |
| 12. | FIXED ASSET INVESTMENTS |
| Group |
| Interest |
| in | Listed |
| associate | investments | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2024 | 209,043 | 783 | 209,826 |
| Share of profit/(loss) | (6,845 | ) | - | (6,845 | ) |
| Exchange differences | - | (36 | ) | (36 | ) |
| At 31 December 2024 | 202,198 | 747 | 202,945 |
| NET BOOK VALUE |
| At 31 December 2024 | 202,198 | 747 | 202,945 |
| At 31 December 2023 | 209,043 | 783 | 209,826 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 12. | FIXED ASSET INVESTMENTS - continued |
| Company |
| Shares in |
| group |
| undertakings |
| £ |
| COST |
| At 1 January 2024 |
| and 31 December 2024 |
| NET BOOK VALUE |
| At 31 December 2024 |
| At 31 December 2023 |
| The group or the company's investments at the Balance Sheet date in the share capital of companies include the following: |
| Subsidiaries |
| Registered office: Leonard House, Great Central Way, Woodford Halse, Daventry, Northamptonshire, NN11 3PZ |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| Registered office: Room 1805, No.481-485 HuaQing South road, QingPu District, 201700 Shanghai City, China |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| Alpha-Cure Asia Limited is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited, which is a 75% subsidiary of Alpha-Cure Group Limited. |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 12. | FIXED ASSET INVESTMENTS - continued |
| Registered office: Von-Siemens-Straße 5,48346 Ostbevern, Deutschland, 48165 Ostbevern, Germany |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| Registered office: 1360 Nanyuan West Road, Qidong Economic Development Zone, Qidong City, Jiangsu Province 226200, China |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| Alpha-Cure (Jiangsu) Co. LTD is a 100% subsidiary of Alpha-Cure Asia Limited, which is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited, which is a 75% subsidiary of Alpha-Cure Group Limited. |
| Registered office: 27 Ashburton Avenue, West Lakes Shore, SA 5020 Australia. |
| Nature of business: |
| % |
| Class of shares: | holding |
| £ | £ |
| Aggregate capital and reserves |
| (Loss)/profit for the year | ( |
) |
| Alpha Cure Australia PTY LTD is excluded from consolidation as it is not material to the group, in size or function. |
| Registered office: Leonard House Unit 2 Great Central Way, Woodford Halse, Daventry, England, NN11 3PZ |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 12. | FIXED ASSET INVESTMENTS - continued |
| Associated company |
| Registered office: ZA DE LA GARE, 9 Rue des Fontaines, 37310 Reignac-sur-Indre, France |
| Nature of business: |
| % |
| Class of shares: | holding |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Aggregate capital and reserves |
| Profit for the year |
| 13. | STOCKS |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Raw materials | 1,526,860 | 1,405,453 |
| Work-in-progress | 52,495 | 65,135 |
| Finished goods | 1,088,466 | 1,169,717 |
| Goods in transit | 375,658 | 227,914 |
| 3,043,479 | 2,868,219 |
| 14. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| Group | Company |
| 31.12.24 | 31.12.23 | 31.12.24 | 31.12.23 |
| £ | £ | £ | £ |
| Trade debtors | 1,984,643 | 1,892,010 |
| Amounts owed by group undertakings | - | - |
| Other debtors | 546,505 | 144,337 |
| Directors' current accounts | 79,651 | 116,245 | - | - |
| Tax | 6,434 | 26,270 |
| Prepayments | 44,216 | 39,104 |
| 2,661,449 | 2,217,966 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 15. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Bank loans and overdrafts (see note 17) | 97,500 | 238,370 |
| Hire purchase contracts (see note 18) | 36,354 | 17,074 |
| Trade creditors | 421,942 | 346,563 |
| Tax | 392,967 | 201,675 |
| Social security and other taxes | 45,587 | 48,228 |
| VAT | 207,109 | 261,523 |
| Other creditors | 736,067 | 171,250 |
| Directors' current accounts | 10,243 | 10,261 |
| Accrued expenses | 56,843 | 93,053 |
| 2,004,612 | 1,387,997 |
| 16. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Bank loans (see note 17) | 268,125 | - |
| Hire purchase contracts (see note 18) | 52,146 | 24,019 |
| 320,271 | 24,019 |
| 17. | LOANS |
| An analysis of the maturity of loans is given below: |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Amounts falling due within one year or on | demand: |
| Bank overdrafts | - | 238,370 |
| Bank loans | 97,500 | - |
| 97,500 | 238,370 |
| Amounts falling due between one and two | years: |
| Bank loans - 1-2 years | 97,500 | - |
| Amounts falling due between two and five | years: |
| Bank loans - 2-5 years | 170,625 | - |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 18. | LEASING AGREEMENTS |
| Minimum lease payments fall due as follows: |
| Group |
| Hire purchase |
| contracts |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Net obligations repayable: |
| Within one year | 36,354 | 17,074 |
| Between one and five years | 52,146 | 24,019 |
| 88,500 | 41,093 |
| Group |
| Non-cancellable |
| operating leases |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Within one year | 123,350 | 133,638 |
| Between one and five years | 7,296 | 107,064 |
| 130,646 | 240,702 |
| 19. | SECURED DEBTS |
| The following secured debts are included within creditors: |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Bank loans | 365,625 | - |
| Hire purchase contracts | 88,500 | - |
| 454,125 | - |
| Included within the Group's creditors are bank loans upon which National Westminster Bank Plc hold debentures dated 2 January 2007 and 8 May 2008 including a first fixed charge on book debts and other debts. |
| All finance lease and hire purchase contracts are secured on assets financed (see note 6). |
| 20. | PROVISIONS FOR LIABILITIES |
| Group |
| 31.12.24 | 31.12.23 |
| £ | £ |
| Deferred tax | 128,966 | 182,192 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 20. | PROVISIONS FOR LIABILITIES - continued |
| Group |
| Deferred |
| tax |
| £ |
| Balance at 1 January 2024 | 182,192 |
| Credit to Income Statement during year | (17,720 | ) |
| Accelerated capital allowances | (35,506 | ) |
| Change in tax rate |
| Balance at 31 December 2024 | 128,966 |
| 21. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 31.12.24 | 31.12.23 |
| value: | £ | £ |
| Ordinary | £1 | 6,000 | 6,000 |
| 22. | RESERVES |
| Group |
| Retained |
| earnings |
| £ |
| At 1 January 2024 | 6,369,450 |
| Profit for the year | 1,971,437 |
| Dividends | (1,793,700 | ) |
| Foreign exchange | (50,447 | ) |
| At 31 December 2024 | 6,496,740 |
| Company |
| Retained | Other |
| earnings | reserves | Totals |
| £ | £ | £ |
| At 1 January 2024 | 11,369,850 |
| Profit for the year |
| Dividends | ( |
) | ( |
) |
| At 31 December 2024 | 11,369,850 |
| Alpha-Cure Group Limited (Registered number: 12267717) |
| Notes to the Consolidated Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 23. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES |
| The following advances and credits to directors subsisted during the years ended 31 December 2024 and 31 December 2023: |
| 31.12.24 | 31.12.23 |
| £ | £ |
| S P Atherstone |
| Balance outstanding at start of year | 26,145 | 26,196 |
| Amounts advanced | 2,037 | - |
| Amounts repaid | (2,507 | ) | (51 | ) |
| Amounts written off | - | - |
| Amounts waived | - | - |
| Balance outstanding at end of year | 25,675 | 26,145 |
| S Haines |
| Balance outstanding at start of year | 60,532 | 1,585 |
| Amounts advanced | 1,796 | 60,000 |
| Amounts repaid | (61,154 | ) | (1,053 | ) |
| Amounts written off | - | - |
| Amounts waived | - | - |
| Balance outstanding at end of year | 1,174 | 60,532 |
| M A Slater |
| Balance outstanding at start of year | 29,568 | (85,547 | ) |
| Amounts advanced | 187,901 | 120,000 |
| Amounts repaid | (164,667 | ) | (4,885 | ) |
| Amounts written off | - | - |
| Amounts waived | - | - |
| Balance outstanding at end of year | 52,802 | 29,568 |
| Loans to the directors are provided with an interest charge at 0% and are repayable on demand. |